Gemeinschaftspraxis für Innere Medizin und Diabetologie
- Address
- Beselerstrasse 2a, 22607 Hamburg, Germany
Cardiovascular Diseases
The Gemeinschaftspraxis für Innere Medizin und Diabetologie is conducting research focused on heart‑related conditions, aiming to evaluate new therapies that could lower cholesterol and reduce major cardiac events.
- LDL‑cholesterol reduction with novel agents
- Lipoprotein(a) lowering to prevent major adverse cardiovascular events
- Assessing cardiovascular risk in patients with established disease
The studies target cardiovascular disease and hypercholesterolemia, seeking to improve patient outcomes through innovative lipid‑lowering treatments.
Nutritional and Metabolic Diseases
Research at the Diabetes Zentrum Hamburg West includes trials addressing obesity and metabolic health, testing combination therapies intended to promote meaningful weight loss.
- Combination drug therapy for weight reduction
- Evaluating percent change in body weight from baseline
- Investigating metabolic improvements in overweight participants
The work targets obesity and related metabolic disorders, aiming to provide safer and more effective options for patients struggling with excess weight.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftspraxis für Innere Medizin und Diabetologie
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of AZD9550 and AZD6234 Co-administration in Obesity or Overweight Patients with Comorbidities: A Phase IIb Randomized Study | AstraZeneca AB | Phase II | Not Recruiting | Feb 2025 | May 2026 |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ascorbic Acid | 1 | Unknown | 2025-02-24 | 2025-02-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.